zinc finger protein like 1Genealiases: D11S750 · MCG4
Q-omics provides the consensus-scored ZFPL1 profile across patient tissues and cancer cell-line models. ZFPL1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZFPL1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ZFPL1 RNA expression shows 19,148 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where ZFPL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFPL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFPL1 survival associations across molecular data types. ZFPL1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFPL1 RNA expression–survival associations across cancer types. High ZFPL1 expression shows unfavorable associations in CESC, KICH, LIHC and ACC, but favorable associations in UCS and SCLC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .015). Together, the overview and detailed table identify UCS as the clearest survival context for ZFPL1 RNA expression.
This table summarizes ZFPL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZFPL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFPL1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUSC, LUAD and BLCA. The HNSC box plot shows higher ZFPL1 RNA expression in tumor versus normal tissue (log2 FC = +0.574, t-test p < 0.001).
This table shows molecular features associated with ZFPL1 in patient tissues and cancer cell lines. In patient samples, ZFPL1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFPL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
